Epidemic
ongoing outbreak of monkeypox in North America, 18 May 2022–present
The 2022–2023 mpox outbreak in North America is a part of the outbreak of human mpox caused by the West African clade of the monkeypox virus. The outbreak reached North America on 18 May 2022, when the United States reported their first case of mpox. As of 23 August 2022, 20 North American countries and territories have confirmed cases.
Fetching the article from Wikipedia…
Text from the Wikipedia article “2022 monkeypox outbreak in North America”, available under CC BY-SA 4.0.
The 2022–2023 mpox outbreak in North America is a part of the outbreak of human mpox caused by the West African clade of the monkeypox virus. The outbreak reached North America on 18 May 2022, when the United States reported their first case of mpox. As of 23 August 2022, 20 North American countries and territories have confirmed cases.
Mpox, originally known as monkeypox, is an infectious viral disease that can occur in humans and other animals. Symptoms include a rash that forms blisters and then crusts over, as well as fever and swollen lymph nodes. The illness is usually mild, and most infected individuals recover within a few weeks without treatment. The time from exposure to the onset of symptoms ranges from three to seventeen days, and symptoms typically last from two to four weeks. However, cases may be severe, especially in children, pregnant women, or people with suppressed immune systems.
The disease is caused by the monkeypox virus, a zoonotic virus in the genus Orthopoxvirus. The variola virus, which causes smallpox, is also in this genus. Human-to-human transmission can occur through direct contact with infected skin or body fluids, including sexual contact. People remain infectious from the onset of symptoms until all the lesions have scabbed and healed. The virus may spread from infected animals through handling infected meat or via bites or scratches. Diagnosis can be confirmed by polymerase chain reaction (PCR) testing a lesion for the virus's DNA.
Vaccination is recommended for those at high risk of infection. No vaccine has been developed specifically against mpox, but smallpox vaccines have been found to be effective. There is no specific treatment for the disease, so the aim of treatment is to manage the symptoms and prevent complications. Antiviral drugs such as tecovirimat can be used to treat mpox, although their effectiveness has not been proven.
An ongoing outbreak of mpox was confirmed on May 6, 2022, beginning with a British resident who, after travelling to Nigeria (where the disease is endemic), presented symptoms consistent with mpox on 29 April 2022. The resident returned to the United Kingdom on May 4, creating the country's index case of the outbreak. The origin of several of the cases of mpox in the United Kingdom is unknown. Some monitors saw community transmission taking place in the London area as of mid-May, but it has been suggested that cases were already spreading in Europe in the previous months.
A large portion of those infected were believed to have not recently traveled to areas of Africa where mpox is normally found, such as Nigeria, the Democratic Republic of the Congo as well as central and western Africa. It is believed to be transmitted by close contact with sick people, with extra caution for those individuals with lesions on their skin or genitals, along with their bedding and clothing. The CDC has also stated that individuals should avoid contact and consumption of dead animals such as rats, squirrels, monkeys and apes along with wild game or lotions derived from animals in Africa.
In addition to more common symptoms, such as fever, headache, swollen lymph nodes, and rashes or lesions, some patients have also experienced proctitis, an inflammation of the rectum lining. CDC has also warned clinicians to not rule out mpox in patients with sexually transmitted infections since there have been reports of co-infections with syphilis, gonorrhea, chlamydia, and herpes.
An index case was imported into the United States on 18 May 2022, by a man who had recently travelled to Canada. He was admitted to a hospital in Massachusetts, likely on 17 May. The day after, the man was confirmed to have contracted mpox. The following day, another mpox case was confirmed, and the United States reported these cases to the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC).
On 19 May, Canada confirmed the first two cases of mpox. Health officials revealed that there was a link between the U.S. case of mpox in Massachusetts and a few of the suspected cases in the Montreal region. The patient of unknown gender or age, may have been infected when recently traveling to Canada. The spread was likely through skin-to-skin contact picked up abroad.
On 28 May, Mexico registered its first case of mpox. It was in a 50-year-old male who resides in the city of New York City and is being treated at Mexico City. It was noted that he may have contracted the disease abroad, from the Netherlands, where there it had already been affected by mpox. It was likely picked up by skin-to-skin contact picked up abroad.
On 29 June, Puerto Rico, a US Territory, confirmed its first case of mpox. It was likely in a male, age between 20 and 50 years old. It is unknown how it was contracted, but likely skin-to-skin contact picked up abroad.
On 30 June, the Bahamas confirmed its first mpox case in a male visitor in his 40s who had most likely contracted the disease from a trip to London, UK, which had already been affected by the mpox outbreak on 9 June. It was likely picked up from skin-to-skin contact abroad.
On 5 July, Panama received its first mpox infection in a resident of unknown gender and age who most likely contracted the disease via contact with tourists from Europe, which had already been affected by the mpox outbreak. It was likely skin-to-skin contact rather than sexual contact.
On 6 July, Jamaica registered its first mpox case. It was in a male of unknown age who had most likely contracted the disease from a trip to London, UK, which had already been affected by the mpox outbreak. It was likely picked up from skin-to-skin contact abroad.
On the same day, the Dominican Republic also confirmed its first case of mpox. It was in a 25-year-old male who had most likely contracted the disease via contact with a person who was infected with mpox in the United States. It was likely skin-to-skin contact rather than sexual contact.
On 16 July, Barbados confirmed its first mpox infection. It was in a Barbadian patient of unknown gender in his 30s. It is unknown how the patient contracted the disease, but likely via skin-to-skin contact abroad.
On 17 July, Martinique, part of Overseas France and a Single territorial collectivity and an Overseas Department of France, received its first mpox case. It was in an adult of unknown exact age and gender who most likely contracted the disease from a trip to a country which had been affected by the mpox outbreak. It was likely picked up via skin-to-skin contact abroad.
On 20 July, Costa Rica recorded its first mpox infection. It was in a 34-year-old male from the United States who resided in Costa Rica for 2 years. He most likely contracted it from a trip to the United States abroad and is considered an imported case. It was likely picked up via skin-to-skin contact.
On 22 July, Bermuda, a British Overseas Territory, although technically part of North America, registered its first mpox case. It is unknown what the patient's gender and age is and how the patient contracted the disease, but it was likely via skin-to-skin contact abroad.
On 25 July, Guadeloupe, part of Overseas France and an Overseas Department of France, confirmed its first case of mpox. It was in a patient of unknown gender or age who resides in Guadeloupe. The patient recently travelled to France and likely contracted the disease via contact with someone in France. It was likely skin-to-skin contact rather than sexual contact.
On 1 August, Collectivity of Saint Martin, part of Overseas France, confirmed its first case of mpox. It was in a patient of unknown gender or age whose residence is unknown. It is unknown how it was contracted, however it may be likely that it was picked up via skin-to-skin contact abroad.
On 3 August, Guatemala registered its first case of mpox. It was in a 31-year-old male who had likely contracted the disease via contact with foreigners/tourists from another country. It was likely skin-to-skin contact rather than sexual contact.
On 9 August, Greenland reported its first two cases of mpox. It was in patients of unknown genders and ages who likely contracted the disease via skin-to-skin contact picked up abroad.
On 12 August, Honduras reported its first case of mpox in an adult male under 50 years of age. It is unknown how the male contracted the disease, although it was likely picked up via contact with other infected abroad.
On 19 August, Curaçao confirmed its first case of mpox in a patient of unknown gender and age who likely contracted the disease abroad, via skin-to-skin contact or sexual contact with others.
On 20 August, Cuba reported its first mpox infection. It was in a male Italian tourist of unknown gender. He most likely contracted the disease from a trip to Italy and other various destinations in the Caribbean. It is unknown how the disease was contracted, but likely via skin-to-skin contact rather than sexual contact.
The man fell into cardiac arrest, likely on the same day he was diagnosed, which he recovered from, but remained in critical condition at the time. He later died on 21 August after rapidly deteriorating. This marked Cuba's first death, as well as North America's first death during the ongoing outbreak.
On 22 August, Aruba reported its first case of mpox. It was in a patient of unknown age and gender who resides in Aruba. It is unknown how the patient contracted the disease, but likely contracted the disease abroad, via skin-to-skin contact or sexual contact with others.
On 20 May, the WHO convened an emergency meeting of independent advisers to discuss the outbreak and assess the threat level. Its European chief, Hans Kluge, expressed concern that infections could accelerate in Europe as people gather for parties and festivals over the summer. On 14 June, the WHO announced plans to rename the disease from monkeypox to mpox in order to combat stigma and racism surrounding the disease. Another meeting convened on 23 June determined that the outbreak does not constitute a Public Health Emergency of International Concern for the time being.
The majority of North American countries responded to the outbreak, and the responses of some are listed below.
Text from the Wikipedia article “2022–2023 mpox outbreak in North America”, available under CC BY-SA 4.0.